Mariusz Bidzinski

Inflancka Street 6
Warsaw, MZ, Poland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 70 publications

Analysis of indocyanine green-guided sentinel lymph node mapping for cervical cancer during pregnancy.

Analysis of indocyanine green-guided sentinel lymph node mapping for cervical cancer during pregnancy.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: March 23, 2026

Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study.

Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study.

Journal: Lancet (London, England)

Published: February 04, 2026

Lenvatinib plus pembrolizumab in participants with advanced or recurrent endometrial cancer: Study 309/KEYNOTE-775 and ENGOT-en9/LEAP-001 post-(neo)adjuvant therapy outcomes.

Lenvatinib plus pembrolizumab in participants with advanced or recurrent endometrial cancer: Study 309/KEYNOTE-775 and ENGOT-en9/LEAP-001 post-(neo)adjuvant therapy outcomes.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: December 17, 2025

First-line lenvatinib plus pembrolizumab versus chemotherapy for advanced endometrial cancer: 1-Year follow-up after final analysis of the ENGOT-en9/LEAP-001 phase 3 trial.

First-line lenvatinib plus pembrolizumab versus chemotherapy for advanced endometrial cancer: 1-Year follow-up after final analysis of the ENGOT-en9/LEAP-001 phase 3 trial.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: September 09, 2025

Real Life Evolution of Surgical Approaches in the Management of Endometrial Cancer in Poland.

Real Life Evolution of Surgical Approaches in the Management of Endometrial Cancer in Poland.

Journal: Cancers

Published: July 22, 2025

Significance of CA125 Monitoring during Maintenance Treatment with Poly(ADP-Ribose) Polymerase Inhibitor in Ovarian Cancer after First-Line Chemotherapy: Multicenter, Observational Study.

Significance of CA125 Monitoring during Maintenance Treatment with Poly(ADP-Ribose) Polymerase Inhibitor in Ovarian Cancer after First-Line Chemotherapy: Multicenter, Observational Study.

Journal: Oncology research

Published: June 02, 2025

Durvalumab with carboplatin/paclitaxel and bevacizumab followed by durvalumab and bevacizumab with or without olaparib maintenance in newly diagnosed non-BRCA-mutated advanced ovarian cancer.

Durvalumab with carboplatin/paclitaxel and bevacizumab followed by durvalumab and bevacizumab with or without olaparib maintenance in newly diagnosed non-BRCA-mutated advanced ovarian cancer.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: May 15, 2025

Systemic recommendations on the promotion of HPV vaccinations based on international social marketing campaigns.

Systemic recommendations on the promotion of HPV vaccinations based on international social marketing campaigns.

Journal: Ginekologia polska

Published: April 20, 2025

Updated Guidelines for the Diagnosis and Treatment of Endometrial Carcinoma: The Polish Society of Gynecological Oncology (2025v).

Updated Guidelines for the Diagnosis and Treatment of Endometrial Carcinoma: The Polish Society of Gynecological Oncology (2025v).

Journal: Current oncology (Toronto, Ont.)

Published: April 14, 2025

Phase II clinical trial of nirogacestat in patients with relapsed ovarian granulosa cell tumours.

Phase II clinical trial of nirogacestat in patients with relapsed ovarian granulosa cell tumours.

Journal: Clinical and translational medicine

Published: April 04, 2025

Safety and efficacy of the therapeutic DNA-based vaccine VB10.16 in combination with atezolizumab in persistent, recurrent or metastatic HPV16-positive cervical cancer: a multicenter, single-arm phase 2a study.

Safety and efficacy of the therapeutic DNA-based vaccine VB10.16 in combination with atezolizumab in persistent, recurrent or metastatic HPV16-positive cervical cancer: a multicenter, single-arm phase 2a study.

Journal: Journal for immunotherapy of cancer

Published: December 23, 2024

Olaparib as Treatment Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer: Phase III SOLO3 Study Final Overall Survival Results.

Olaparib as Treatment Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer: Phase III SOLO3 Study Final Overall Survival Results.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: December 12, 2024

Showing 1-12 of 70

Last Updated: 09/26/2026